RhoVac Past Earnings Performance
Past criteria checks 0/6
RhoVac's earnings have been declining at an average annual rate of -30.7%, while the Biotechs industry saw earnings growing at 2.5% annually.
Key information
-30.7%
Earnings growth rate
-12.2%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | n/a |
| Return on equity | -393.7% |
| Net Margin | n/a |
| Next Earnings Update | 27 Feb 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How RhoVac makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -50 | 62 | 0 |
| 30 Jun 22 | 0 | -68 | 77 | 0 |
| 31 Mar 22 | 0 | -60 | 75 | 0 |
| 31 Dec 21 | 0 | -55 | 72 | 0 |
| 30 Sep 21 | 0 | -49 | 67 | 0 |
| 30 Jun 21 | 0 | -44 | 62 | 0 |
| 31 Mar 21 | 0 | -43 | 58 | 0 |
| 31 Dec 20 | 0 | -40 | 53 | 0 |
| 30 Sep 20 | 0 | -24 | 78 | 0 |
| 30 Jun 20 | 0 | -23 | 66 | 0 |
| 31 Mar 20 | 0 | -35 | 46 | 0 |
| 31 Dec 19 | 0 | -34 | 42 | 0 |
| 30 Sep 19 | 0 | -42 | 10 | 0 |
| 30 Jun 19 | 0 | -37 | 13 | 0 |
| 31 Mar 19 | 0 | -20 | 22 | 0 |
| 31 Dec 18 | 0 | -17 | 20 | 0 |
| 30 Sep 18 | 0 | -14 | 16 | 0 |
| 30 Jun 18 | 0 | -13 | 15 | 0 |
| 31 Mar 18 | 0 | -12 | 14 | 0 |
| 31 Dec 17 | 0 | -11 | 13 | 0 |
| 30 Sep 17 | 0 | -12 | 15 | 0 |
| 30 Jun 17 | 0 | -12 | 14 | 0 |
| 31 Mar 17 | 0 | -12 | 13 | 0 |
| 31 Dec 16 | 0 | -11 | 13 | 0 |
| 30 Sep 16 | 0 | -9 | 10 | 0 |
| 30 Jun 16 | 0 | -6 | 6 | 0 |
Quality Earnings: RHOVAC is currently unprofitable.
Growing Profit Margin: RHOVAC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RHOVAC is unprofitable, and losses have increased over the past 5 years at a rate of 30.7% per year.
Accelerating Growth: Unable to compare RHOVAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RHOVAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.9%).
Return on Equity
High ROE: RHOVAC has a negative Return on Equity (-393.73%), as it is currently unprofitable.